Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Apr 15, 2021 5:05pm
107 Views
Post# 33005365

RE:RE:RE:The problem

RE:RE:RE:The problemAs your own experience suggests, it does not seem that communicating with the company has a lot of favorable impact. In the Fall when the new board members were announed, I asked to speak with the Chairwoman of the board to get her insights into their skills and how they might help the company. At the time I was the largest shareholder (at least as far as the public records reveal) and a very long term shareholder of the company. I was told management did not feel that was a necessary meeting. 

Doing a share offering at too low of a price was certainly something that had been communicated repeatedly over the years and that obviously was not something that had the desired impact. 

So, I am not sure it will make a diffference if we communicate with them although it is fair to also say some suggestions over the years were taken and acted on. Hopefully, we will see more changes we can all get enthusiastic about very soon as time is running out, and the need for us to offer the company our wisdom will no longer even be necessary. But as long as TH's stock price is were it is while other stocks prices are where they are, the incentives to stir things up in the only way we are able to do so (voting our shares at the AGM) are pretty high.   

While we are talking about sugestions to management, I have one. Ask somebody to research how many companies presenting pre-clinical research at the AACR meeting had Fast Track status from the FDA. TH  may well ahve been the only one and it is a fun fact to be able to give to potential investors. It might be worth finding out how many companies presenting there who were in phase I had already been granted Fast Track status. If TH has something special that distinguishes it from other companies, don't hide such information. Repeat it at least three times in every presentation.

scarlet1967 wrote: Unfortunately although there have been so many great suggestions on this MB not many have been directly communicating their ideas with the company. In a sense what is going on here is very similar to what has been going on at the company which is a lot of talking but not much action.
After been emailing Leah multiple times per month for more than a year sharing yours and my suggestions with no obvious changes I requested to talk to her although she seemed to agree with me on many issues and assured me there will be many surprising changes in the following months here we are again a lot of talking but no action.
I certainly hope all the time consuming great works by posters here get communicated by the same posters with the company. The effect of many active shareholders interaction with the company is much better than only one or two.


<< Previous
Bullboard Posts
Next >>